Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors

J.M. Stephens, Pharmerit North America LLC, 7272 Wisconsin Ave., Bethesda, MD 20814-4858, United States e-mail: jstephens@pharmerit.com.

Expert Opinion on Pharmacotherapy. 2007;8((8):):1127-36.
Full text from:
Study details
Study Design : Economic Study
Additional Material : Also reported as: Stephens JM, Botteman MF, Joshi AV, Sumner M. Health economic review of recombinant activated factor VII (Novoseven) for treatment of bleeding episodes in hemophilia patients with inhibitors. 48th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, 9 December 2006. Blood 2006, 108(11): Abstract No. 5539. (<a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/5539)">http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/5539)</a>
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine